Carol Gallagher

Dr. Gallagher joined NEA as a Partner in October, 2014. She is a proven entrepreneur, operator and more recently investor with nearly 30 years of experience in commercial, drug development and business development roles at large and small pharmaceutical companies. From 2008-2011, Dr. Gallagher was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG. After the sale of Calistoga Pharmaceuticals, she spent several years serving as an independent director on multiple biopharma company boards before pursuing a career in venture capital. She currently serves as Chairman of the Board at Millendo Therapeutics, lead director at Atara Bio, and as a director at Metacrine, PIONYR Immunotherapeutics, Cleave Biosciences and AnaptysBio.